Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Hansa Biopharma :  Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen

09/17/2020 | 02:10am EST
09/17/2020

Focusing on transformation into a commercial stage biopharmaceutical company and the potential of its unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy

Lund, Sweden September 17, 2020. Hansa Biopharma ('Hansa'), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company will host its 2020 Capital Markets Day (CMD) in Copenhagen on Thursday October 29, from 13:30-17:30 CET (7:30am-11:30am EST).

The CMD event will be focused around Hansa Biopharma's transformation into a fully integrated and commercial stage biopharmaceutical company and will highlight the potential of the Company's unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy.

The event will feature both senior management and external guest speakers. A detailed agenda is expected to be shared to registrants a few weeks ahead of the CMD. The event will be livestreamed and available for all viewers on our web at http://www.hansabiopharma.com.

If you wish to participate in the CMD virtually, kindly sign up using the following link here.

Due to the COVID-19 pandemic, there will be limitations to the number of physical participants at the CMD. In-person invitations will go out separetaly by email to select institutional investors, analysts and media.

Multimedia Files:

Categories:Cision

Disclaimer

Hansa Biopharma AB published this content on 17 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2020 06:09:04 UTC


© Publicnow 2020
All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
More news
Financials
Sales 2020 35,8 M 4,26 M 4,26 M
Net income 2020 -396 M -47,3 M -47,3 M
Net cash 2020 1 385 M 165 M 165 M
P/E ratio 2020 -19,4x
Yield 2020 -
Capitalization 8 130 M 971 M 969 M
EV / Sales 2020 189x
EV / Sales 2021 73,9x
Nbr of Employees 80
Free-Float 95,9%
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 182,80 SEK
Spread / Highest target 124%
Spread / Average Target 61,7%
Spread / Lowest Target 3,94%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.96%971
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601